Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 14/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703315 | 0.88 | AXL (0.50) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL2946536 | 0.86 | AXL (0.44) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL2946115 | 0.85 | ADORA3 (0.48) | MERTKTTKADORA3ADORA1ADORA2A | |
| Ammonia Solution, Strong SCHEMBL3705254 | 0.85 | PRKDC (0.36) | AXLMERTKTTK | |
| SCHEMBL3698227 | 0.85 | AXL (0.47) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL2951204 | 0.85 | AXL (0.47) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL4766705 | 0.84 | AXL (0.45) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL4764869 | 0.84 | TTK (0.54) | TTK | |
| SCHEMBL2950079 | 0.84 | MERTK (0.50) | AXLMERTKTTKADORA3ADORA1 | |
| SCHEMBL2954639 | 0.84 | AXL (0.46) | AXLMERTKTTKADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | AXL 2976/4885MERTK 1662/4885TTK 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.